Business · 06/09/2022
FDA Awards Priority Review Voucher to BioMarin Pharmaceutical for Rare Pediatric Disease Product VOXZOGO
The FDA has issued a priority review voucher to BioMarin Pharmaceutical, Inc. for its rare pediatric disease product VOXZOGO, following a review of the product's eligibility under the Federal Food, Drug, and Cosmetic Act.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →